tirzepatide delayed gastric emptying Tirzepatide works by targeting GLP-1 and GIP receptors to help regulate Implications of the glp-1 era

Preclinical in vitro evidence for the efficacy of incretin receptor agonists is derived primarily from epithelial, immune, and vascular cellular models rather than from direct studies of lung fibroblasts

these side effects are inherent with intravenous infusion of any substance

In biosimilars specifically, scale matters: the economics favor manufacturers capable of competing on both price and supply reliability simultaneously, because payers and PBMs will not accept single-source biosimilar supply after watching supply disruptions across the generic small-molecule market

Moving forward, the most realistic near-term translational path lies in combining relatively simple, biocompatible bone-targeted nanocarriers (such as alendronate-functionalized liposomal or polymeric systems) to specifically co-deliver immunogenic cell death (ICD)-inducing standard chemotherapeutics alongside established immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1) or myeloid cell modulators